European CHMP Adopts Positive Opinion for Treatment of All Genotypes of Chronic Hepatitis C

3 June 2016
79 Views

Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company’s Marketing Authorization Application (MAA) for an investigational, pan-genotypic, once-daily tablet containing the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400 mg and velpatasvir (VEL) 100 mg, an investigational pan-genotypic NS5A inhibitor, for the treatment of chronic hepatitis C virus (HCV) infection. The data included in the application support the use of Epclusa (SOF/VEL) in adults with all genotypes (GT1-6) of HCV infection.

The CHMP positive opinion was adopted following an accelerated review procedure, reserved for medicinal products expected to be of major public health interest. The recommendation will now be reviewed by the European Commission, which has the authority to approve medicines for use in the 28 countries of the European Union, Norway and Iceland.

You may be interested

Anafi: Straight out of the Greek Mythology
GREECE
shares64 views
GREECE
shares64 views

Anafi: Straight out of the Greek Mythology

Panos - Aug 17, 2017

Greek Mythology has it that Anáfi, a paradise of pristine beauty and “exotic” beaches washed by crystal clear waters, had…

Greek Government to Invest in Kastellorizo Island Desalination
FINANCE
shares81 views
FINANCE
shares81 views

Greek Government to Invest in Kastellorizo Island Desalination

Panos - Aug 17, 2017

Greece’s General Secretariat for the Aegean and Island Policy and the country’s shipping industry have signed a €870,000 ($1 million)…

How will Turkey survive until 2019?
GREECE
shares74 views
GREECE
shares74 views

How will Turkey survive until 2019?

Panos - Aug 17, 2017

Politics in Turkey is entering a highly stressful two years this fall. Since the referendum, President Recep Tayyip Erdoğan seems…

Leave a Comment

Your email address will not be published.